更新于：2024-11-01

MMP1

更新于：2024-11-01

基本信息

别名

22 kDa interstitial collagenase、27 kDa interstitial collagenase、CLG

+ [8]

简介

Cleaves collagens of types I, II, and III at one site in the helical domain. Also cleaves collagens of types VII and X (PubMed:2557822, PubMed:2153297, PubMed:1645757). In case of HIV infection, interacts and cleaves the secreted viral Tat protein, leading to a decrease in neuronal Tat's mediated neurotoxicity (PubMed:16807369).

关联

项与 MMP1 相关的药物

FCX-013

靶点

MMP1

作用机制

MMP1基因转移

在研机构

Fibrocell Science, Inc.

原研机构

Fibrocell Science, Inc.

在研适应症

系统性硬皮病

非在研适应症

局部硬皮病

最高研发阶段临床申请

首次获批国家/地区-

首次获批日期1800-01-20

RXI-185

靶点

MMP1

作用机制

MMP1抑制剂

在研机构

Phio Pharmaceuticals Corp.

原研机构

Phio Pharmaceuticals Corp.

在研适应症

皮肤松弛症 [+1]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

Anti-MMP1 RNAi (Phio Pharmaceuticals)

靶点

MMP1

作用机制

MMP1抑制剂

在研机构

Phio Pharmaceuticals Corp.

原研机构

Phio Pharmaceuticals Corp.

在研适应症

肿瘤 [+2]

非在研适应症-

最高研发阶段药物发现

首次获批国家/地区-

首次获批日期1800-01-20

项与 MMP1 相关的临床试验

NCT03740724 / Terminated临床1/2期

A Phase 1/2 Study of a Combination of FCX-013 (Genetically-Modified Autologous Human Dermal Fibroblasts) Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

A two-component therapeutic consisting of FCX-013 and veledimex for the treatment of localized scleroderma (or morphea). The first component, FCX-013, is autologous human fibroblasts genetically-modified using lentivirus and encoded for matrix metalloproteinase 1 (MMP-1), a protein responsible for breaking down collagen. FCX-013 is designed to be injected under the skin at the location of the fibrotic lesions where the genetically-modified fibroblast cells will produce MMP-1 to break down excess collagen accumulation. With the FCX-013 therapy, the patient will take an oral compound (Veledimex) to induce MMP-1 protein expression from the injected cells. Once the fibrosis is resolved, the patient will stop taking the oral compound which will stop further MMP-1 production from the injected cells. FCX-013 plus veledimex is being developed in anticipation of improving skin function in patients by resolving fibrotic lesions and normalizing dermal collagen production

开始日期2019-12-18

申办/合作机构-

NCT00040755 / Completed临床2期IIT

Randomized Phase II Trial of BMS-275291 (NSC 713763, IND 62573) in Hormone Refractory Prostate Cancer

BMS-275291 may stop the growth of prostate cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Randomized phase II trial to study the effectiveness of BMS-275291 in treating patients who have prostate cancer that has not responded to hormone therapy

开始日期2002-05-01

申办/合作机构

National Cancer Institute

NCT00039104 / Completed临床2期IIT

A Phase II, Open-Label, Randomized Trial of Zoledronic Acid (Zometa™) and BMS-275291 (NSC#713763) in Patients With Hormone Refractory Prostate Cancer

Phase II trial to study the effectiveness of combining zoledronate with BMS-275291 in treating patients who have prostate cancer that has not responded to previous hormone therapy. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. BMS-275291 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Combining zoledronate with BMS-275291 may kill more tumor cells.

开始日期2002-04-01

申办/合作机构

National Cancer Institute

100 项与 MMP1 相关的临床结果

登录后查看更多信息

100 项与 MMP1 相关的转化医学

登录后查看更多信息

0 项与 MMP1 相关的专利（医药）

登录后查看更多信息

9,469

项与 MMP1 相关的文献（医药）

2025-01-01·Gene

Matrix metalloproteinases: Master regulators of tissue morphogenesis

Review

作者: Aradhya, Rajaguru ; Amrutha, R ; Suravajhala, Prashanth ; Vandana ; Jyothis, Anjali ; Venugopal, Parvathy ; Chavan, Yash ; Sreesada, P ; Alfia, Hasanath ; Krishnan, Bhagath ; Nair, Bipin G

The matrix metalloproteinases (MMPs) are a class of zinc proteases that aid in breaking most of the extracellular matrix's (ECM) constituents. Additionally, MMPs play a part in processing elements that affect inflammation, cell development and proliferation, and many more. In vivo genetic study of the Drosophila MMPs Mmp1 and Mmp2 reveals they are essential for tissue remodeling but not embryonic development. The canonical and conserved MMP domain organization is present in both fly MMPs. Because Mmp2 appeared to be membrane-anchored and Mmp1 appeared to be released, the pericellular localization of Drosophila MMPs has been used to classify them. This suggests that the protein's localization is the critical distinction in this small MMP family. The signal sequence, the propeptide, the catalytic domain, and the hemopexin-like domain are among the numerous domains found in MMPs. Following secretion from the extracellular environment to the endoplasmic reticulum, the pre-domain, also known as the signal sequence, serves to direct MMP production. MMPs of the secretory and membrane types (MT-MMPs) are two groups of MMPs that have been widely recognized. Subgroups of MMPs are categorized based on their structure and function. While analysis of the intracellular activity of human MMPs is challenging because the human genome contains around 23 distinct MMPs with overlapping functions, only two MMPs, dMMP1 and dMMP2, are encoded by the Drosophila melanogaster genome. On the other hand, the balance between MMPs and the family members are implicated in various pathophysiology/progression of diseases, but whether or not the mechanisms of MMP inhibition are not clearly understood as master regulators. In this review, we outline the role of MMPs as master regulators of tissue morphogenesis.

2024-12-31·Emerging Microbes & Infections

Plasma immune profiling combined with machine learning contributes to diagnosis and prognosis of active pulmonary tuberculosis

Article

作者: Li, Guobao ; Xu, Yuzhong ; Huang, Yiting ; Li, Wei ; Ou, Min ; Xu, Hui ; Zhang, Ruiqi ; Song, Jiaping ; Yao, Fusheng ; Zhang, Guoliang ; Lin, Qiao

Tuberculosis (TB) remains one of the deadliest chronic infectious diseases globally. Early diagnosis not only prevents the spread of TB but also ensures effective treatment. However, the absence of non-sputum-based diagnostic tests often leads to delayed TB diagnoses. Inflammation is a hallmark of TB, we aimed to identify biomarkers associated with TB based on immune profiling. We collected 222 plasma samples from healthy controls (HCs), disease controls (non-TB pneumonia; PN), patients with TB (TB), and cured TB cases (RxTB). A high-throughput protein detection technology, multiplex proximity extension assays (PEA), was applied to measure the levels of 92 immune proteins. Based on differential analysis and the correlation with TB severity, we selected 9 biomarkers (CXCL9, PDL1, CDCP1, CCL28, CCL23, CCL19, MMP1, IFNγ and TRANCE) and explored their diagnostic capabilities through 7 machine learning methods. We identified combination of these 9 biomarkers that distinguish TB cases from controls with an area under the receiver operating characteristic curve (AUROC) of 0.89-0.99, with a sensitivity of 82-93% at a specificity of 88-92%. Moreover, the model excels in distinguishing severe TB cases, achieving AUROC exceeding 0.95, sensitivities and specificities exceeding 93.3%. In summary, utilizing targeted proteomics and machine learning, we identified a 9 plasma proteins signature that demonstrates significant potential for accurate TB diagnosis and clinical outcome prediction.

2024-12-31·Pharmaceutical Biology

Exploring the wound-healing potential and seasonal chemical variability of the Formosan Callery pear Pyrus calleryana : implications for therapeutic applications

Article

作者: Lai, Kuei-Hung ; Tang, Xin-Yun ; Peng, Bo-Rong ; Chen, Yun-Shiuan ; Lee, Mei-Hsien

CONTEXTPyrus calleryana Decne (Rosaceae), renowned for its therapeutic properties, is known to moisturize the lungs (removing dryness; relieving cough), clear heat (acting as an antipyretic; febrifuge) and aid in detoxification (relieving pyogenic inflammation; eliminating toxins). However, scientific evidence supporting its efficacy in wound healing is lacking.OBJECTIVEThis study investigated P. calleryana samples collected over a year to explore metabolite variations and their impact on skin wound-healing activities.MATERIALS AND METHODSP. calleryana (PC) twigs and leaves were collected from the Matsu Islands, Taiwan, spanning 2018-2020. Extracts were prepared using 95% ethanol or water, and we assessed the chemical composition, total phenolic/triterpenoid contents and antioxidant properties. Metabolites were analysed via LC-MS/MS and molecular networking. Wound healing potential was evaluated on WS-1 cells through MTT and migration assays, and gene expression analyses, with tests including control (DMSO), compounds 1 (3'-hydroxylbenzyl-4-hydroxybenzoate-4'-O-β-glucopyranoside) and 2 (vanilloylcalleryanin) (100 µM), and a positive control (ascorbic acid, 100 µM) for 24 h.RESULTSSignificant variations in extract compositions were observed based on the solvent used, with distinct metabolomic profiles in extracts collected during different months. Notably, compounds 1 and 2 showed no cytotoxic effects on human dermal fibroblast cells and significantly accelerated wound closure at 100 μM. A gene expression analysis indicated upregulation of wound healing-associated genes, including MMP-1 (matrix metalloproteinase-1) and COL1A1 (collagen, type 1, alpha 1).CONCLUSIONSThis study reports the first evidence of PC compounds aiding wound healing. Utilizing Global Natural Products Social Molecular Networking (GNPS) and principal component analysis (PCA) approaches, we unveiled metabolomic profiles, suggesting the potential to expedite wound-healing.

项与 MMP1 相关的新闻（医药）

2024-09-20

·Abiosciences

Cancer Cell | 张泽民团队通过跨组织单细胞多组学揭示肌成纤维细胞的多样化免疫调节特征

成纤维细胞是维持组织稳态的关键结构细胞，在纤维化、炎症和癌症等疾病状态下呈现出多种表型来影响疾病进程及其治疗抗性[1,2]。肌成纤维细胞（myofibroblasts）因其对肿瘤微环境的关键调控作用，近年来受到广泛关注。研究发现，它们在胰腺癌、乳腺癌和结肠癌等多种癌症中表现出显著的免疫抑制作用[3-5]；然而，肌成纤维细胞的异质性、在不同疾病状态下的分布特征、空间定位及其与其它免疫细胞的互作机制仍有待深入研究。 2024年9月19日，百奥智汇创始人、科学顾问，北京大学生物医学前沿创新中心（BIOPIC）/深圳湾实验室张泽民院士课题组在Cancer Cell上发表题为Cross-tissue human fibroblast atlas reveals myofibroblast subtypes with distinct roles in immune modulation的研究。该研究基于健康、纤维化、炎症以及癌症等多种疾病状态下的11种组织的单细胞数据，构建了涵盖517个人类样本、269,899个成纤维细胞的图谱，并鉴定出20种成纤维细胞亚型，揭示了成纤维细胞未被充分认识的转录异质性，其中发现了4类具有独特表型的肌成纤维细胞亚型。通过整合空间转录组、多重免疫组化和体外实验，该研究进一步揭示了肌成纤维细胞在肿瘤微环境中的独特免疫调控功能，为开发肿瘤微环境特异性靶向治疗策略提供了新的思路。这项研究揭示了组织和疾病环境在塑造成纤维细胞表型及其分布中的关键作用。在慢性炎症和纤维化疾病中，肌成纤维细胞亚型逐渐增多，并在癌症进展过程中不断累积，表明肿瘤环境对成纤维细胞表型的重塑作用。通过调控成纤维细胞的信号传导和代谢通路，最终促成了免疫抑制肿瘤微环境的形成。这些发现为成纤维细胞转录可塑性提供了有力证据，支持了成纤维细胞从启动和支持炎症到最终抑制炎症的不同表型之间动态转换的观点[2]。相比于其他肌成纤维细胞亚型，LRRC15+ 肌成纤维细胞表现出终末分化特征，可能来源于两大细胞亚型——祖细胞样成纤维细胞（PI16+ 和 COL15A1+）以及周细胞（RGS5+）。多重免疫组化染色进一步证实，在肿瘤区域表达周细胞标志物（MCAM+、PDGFRβ+）的LRRC15+ 成纤维细胞，表明其潜在的周细胞来源。而PI16+ 成纤维细胞则位于癌旁间质区域，研究揭示特定细胞因子促进其表型形成。进一步研究这些成纤维细胞亚型与免疫细胞的互作模式和空间定位特征，发现PI16+ 成纤维细胞和LRRC15+ 成纤维细胞在多种癌症类型中参与了不同的空间多细胞模块（CMs）。其中PI16+ 成纤维细胞与CX3CR1+ Temra细胞和LYVE1+ 巨噬细胞相互作用，表现出抗肿瘤免疫特征；而LRRC15+ 成纤维细胞则与SPP1+ 巨噬细胞共定位于癌巢区域，显示出免疫排斥功能。根据成纤维细胞祖细胞或终末分化肌成纤维细胞的丰度对肿瘤患者进行分型，发现其在多个癌种中具有显著预后差异，支持两种成纤维细胞亚型在肿瘤微环境中的不同作用，该发现为患者分型和临床治疗策略提供了新方向。此外，这项研究还发现了一类具有炎性特征的MMP1+肌成纤维细胞，通过与Treg细胞和LAMP3+树突状细胞共同构建免疫抑制微环境来促进免疫逃逸。MMP1+成纤维细胞可能通过CCL2-CCR4等途径招募Treg细胞，并通过分泌TGF-β和IL-11促进免疫耐受环境的形成，通过分泌MMPs等蛋白参与组织重塑，进一步影响免疫细胞的迁移和功能。MMP1+和LRRC15+成纤维细胞特征在不同癌种的免疫治疗无响应者中显著富集，表明它们在特定癌种中有望成为癌症治疗中的联合治疗靶点。图1. 人类跨组织成纤维细胞图谱概览图综上所述，该研究全面探讨了在不同组织和疾病背景下成纤维细胞的表型和分布特征，并揭示了不同肌成纤维细胞在免疫调控中的独特作用。这些发现将进一步深化对疾病相关成纤维细胞的理解，并为患者分型和开发新的联合治疗方案提供重要线索。深圳湾实验室助理研究员高洋、昌平实验室助理研究员李佳楠、北京大学前沿交叉学科研究院CLS项目博士生程文凤为该论文的并列第一作者，北京大学BIOPIC张泽民院士、广东医科大学附属东莞第一医院的侯文洪博士为该论文的共同通讯作者。研究得到了深圳湾实验室重大项目和深圳湾实验室开放基金、中国博士后科学基金和粤莞联合基金的资助。深圳湾实验室超算中心为该研究提供了计算资源支持。论文链接：https://www-sciencedirect-com.libproxy1.nus.edu.sg/science/article/pii/S1535610824003192 参考文献: 1.Biffi, G., and Tuveson, D.A. (2021). Diversity and Biology of Cancer-Associated Fibroblasts. Physiol Rev 101, 147-176. 10.1152/physrev.00048.2019. 2.Davidson, S., Coles, M., Thomas, T., Kollias, G., Ludewig, B., Turley, S., Brenner, M., and Buckley, C.D. (2021). Fibroblasts as immune regulators in infection, inflammation and cancer. Nat Rev Immunol 21, 704-717. 10.1038/s41577-021-00540-z. 3.Krishnamurty, A.T., Shyer, J.A., Thai, M., Gandham, V., Buechler, M.B., Yang, Y.A., Pradhan, R.N., Wang, A.W., Sanchez, P.L., Qu, Y., et al. (2022). LRRC15(+) myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature 611, 148-154. 10.1038/s41586-022-05272-1. 4.Foster, D.S., Januszyk, M., Delitto, D., Yost, K.E., Griffin, M., Guo, J., Guardino, N., Delitto, A.E., Chinta, M., Burcham, A.R., et al. (2022). Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin. Cancer Cell 40, 1392-1406.e1397. 10.1016/j.ccell.2022.09.015. 5.Qi, J., Sun, H., Zhang, Y., Wang, Z., Xun, Z., Li, Z., Ding, X., Bao, R., Hong, L., Jia, W., et al. (2022). Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer. Nat Commun 13, 1742. 10.1038/s41467-022-29366-6. 张泽民，北京大学生物医学前沿创新中心主任，北京大学生命科学学院终身讲席教授，北大-清华生命科学联合中心高级研究员，长江学者，中国科学院院士。张泽民博士的学术经历包括南开大学、CUSBEA项目（中美生物化学联合招生项目）、美国宾夕法尼亚州立大学和加州大学旧金山分校。在 2014 年加入北大以前就任基因泰克/ 罗氏公司（Genentech/Roche）16余年，负责生物信息学和癌症基因组学研究，挖掘抗癌靶点。张泽民课题组致力于用前沿的生物信息和基因组学来解决癌症生物学中的核心问题，专注于研究肿瘤微环境的底层特征，发现了肿瘤在微环境水平的异质性和潜在规律，推进其在药物疗效预测和靶点发现中的应用。张泽民课题组的研究成果曾获得北京市自然科学一等奖、中国生命科学十大进展、中国生物信息十大进展（多次）。他也是几个国际顶尖杂志的编委，包括Cell, Cancer Cell, Cancer Discovery和Cell Research。张泽民课题组目前主要的研究方向包括：（1）研究肿瘤微环境特别是肿瘤浸润免疫细胞的精确组成、相互作用以及功能状态，并鉴定影响这些细胞功能的调控基因；（2）研究肿瘤微环境的异质性、及其对癌症病人治疗的影响；（3）开发原创的生物信息学工具和数据库，来进行大数据的整合、分析和可视化。本文来源：北京大学生物医学前沿创新中心百奥智汇一站式解决方案关于百奥智汇百奥智汇成立于2018年，是一家拥有全球视野的生命科学技术公司，致力于将单细胞机理研究平台和生物信息学大数据/AI平台充分应用于癌症等重大人类疾病的诊断和治疗中，充分利用自身强大的科研能力、自有平台和数据，创建人类疾病的精准细胞图谱，寻找具突破性的疾病诊断和治疗靶标、开发颠覆性的治疗方法。欲了解更多关于百奥智汇的信息或服务，可通过下方的通讯方式联系我们。

免疫疗法

2024-06-25

·CPHI制药在线

ADC闪耀2024 ASCO，“雪藏”的LIV-1靶点还有未来吗？

关注并星标CPHI制药在线 LIV-1，又称SLC39A6或ZIP6，属于锌转运蛋白SLC39A家族。SLC39A家族被证明可促进细胞外或细胞器内的锌离子转运到细胞质，具有锌离子吸收（influx）摄取功能。该家族包含14个成员，可分为4个亚家族，即ZIP-I（ZIP9）、ZIP-II（ZIP1-3）、gufA（ZIP11）和 LIV-1（ZIP4-8，ZIP10，ZIP12-14）。而锌离子在信号转导、基因表达、减数分裂、免疫功能、凋亡控制和细胞周期进程等生命活动中发挥重要作用。关于LIV-1 LIV-1蛋白包括6-8个跨膜域，氨基和羧基末端均位于细胞外或囊泡内，其中第3和4跨膜域间存在富含组氨酸的结构域，该区域具有结合锌离子的功能，并具有金属蛋白酶活性。LIV-1主要功能是将锌离子从细胞外转移至细胞内，并且是酶、转录因子和信号分子发挥作用机制中的关键蛋白。 LIV-1在组织的表达具有异质性，主要表达在激素控制组织中，且表达对雌激素水平敏感。LIV-1最早作为雌激素调节基因被发现存在于淋巴结累及的乳腺癌中，近年来研究发现其在乳腺癌、前列腺癌、胰腺癌、宫颈癌和肝癌等多种肿瘤细胞中高表达，但在正常组织有限表达。LIV-1在不同肿瘤中的表达率不同，文献显示其在乳腺癌中表达率达93%，黑色素瘤中表达率为82%，前列腺癌中表达率为72%，卵巢癌中为48%，子宫癌中为30%，肺癌中为10%。作为肿瘤相关的潜力分子，LIV-1在肿瘤发生过程的分子机制复杂，有待进一步阐明。信号转导及转录激活因子３（STAT3）和锌指蛋白（Snail）是上皮间质转化（EMT）通路的主要标志物。LIV-1是STAT3的下游靶基因，促进锌指蛋白Snail的入核。而Snail基因可降低与细胞黏附有关的基因表达，在上皮细胞转化为间质细胞的过程中起重要作用。因此，LIV-1可通过影响Snail表达，调节细胞分化过程。但在不同肿瘤中，LIV-1的作用机制有所不同。研究发现，在乳腺癌中，LIV-1运输锌离子进入细胞，会抑制GSK3β的活性，失活的GSK3β不能磷酸化Snail，使Snail留在核内抑制细胞交联基因E-cadherin的转录，促进细胞迁移。在食管鳞癌中，LIV-1是STAT3的下游靶基因，LIV-1通过调控Snail2基因，参与食管鳞癌的EMT过程。此外，研究发现，肿瘤微环境中LIV-1的表达会被例如EGF、IGF-1等生长因子所激活。在前列腺肿瘤细胞系中，LIV-1过表达会引起EGFR磷酸化和ERK磷酸化，其下游信号可诱导细胞的迁移和入侵行为。在食管癌中，过表达LIV-1的细胞，可激活AKT和ERK通路，调节MMP1、MMP3、MYC和SLUG表达。 LIV-1靶点进展 LIV-1被认为是肿瘤药研发的潜力靶点，目前全球药企针对该靶点已开发出几款药物，如Ladiratuzumab vedotin（SGN-LIV1A，Seagen）、BRY812（博锐生物）、HLX41（复宏汉霖），其中Ladiratuzumab vedotin（SGN-LIV1A）进展最快，目前已进入2期临床。 Ladiratuzumab vedotin（SGN-LIV1A）是Seagen开发的一款ADC，由LIV1靶向人源化IgG1单抗SLC39A6和Seagen经典的mc-VC-MMAE偶联而出，DAR值为4。Ladiratuzumab vedotin被开发用于治疗三阴性乳腺癌（TNBC）等实体瘤，2021年ESMO年会公布的临床1/2期研究数据显示：ladiratuzumab vedotin每周一次给药治疗安全性可控，且有初步抗肿瘤活性，二线治疗29例转移性TNBC的ORR为28%；另一项1b/2期临床研究数据显示：ladiratuzumab vedotin联合帕博利珠单抗治疗TNBC的ORR为35%，且对初诊时即为IV期或此前接受过辅助/新辅助治疗的患者均能诱导缓解。 2020年9月，Seagen与默沙东达成2项新的肿瘤学战略合作，其中包括ladiratuzumab vedotin方面签订的总价值42亿美元的合作。然而，由于TNBC领域竞争激烈，新疗法的出现导致药物开发需要达到更高的疗效阈值，2023年默沙东在发布2023H1财报时宣布降低开发ladiratuzumab vedotin的优先级。 BRY812是国内首款获批临床的LIV-1靶向ADC，其采用博锐生物CysLink不可逆化学偶联技术平台和高度稳定的连接子，将LIV-1靶向抗体与小分子毒素偶联。BRY812可识别肿瘤细胞表面过表达的LIV-1，并与其结合，ADC-靶点复合物通过内吞作用进入肿瘤细胞溶酶体内，释放小分子毒素杀伤肿瘤细胞。2023年7月，BRY812在国内获批临床，拟用于治疗晚期恶性肿瘤。临床前研究显示：BRY812具有明显的肿瘤生长抑制效果，具备潜在同类最佳的抗肿瘤活性，相比于其他同类药物具有更稳定的循环稳定性，能在肿瘤中有效释放载荷的同时增强ADC循环稳定性，显著减少毒素的脱落和交换，具有良好的安全性及更优的治疗窗。此外，BRY812能够诱导免疫原性细胞死亡（ICD），增强 PD(L)-1 等免疫疗法的抗肿瘤作用。总结 ADC是目前研发非常火热的一条赛道，在今年ASCO大会上更是大放异彩。但相较于HER2、TROP2、Nectin-4等热门靶点，LIV-1进展相对较慢，且在研药物较少，进展较快的ladiratuzumab vedotin治疗TNBC的临床试验数据并不很亮眼。我国药企在LIV-1领域也有布局，但鉴于该靶点进展状况，研发失败的风险还是挺高的。不过，总有人要做第一个吃螃蟹的人，期待LIV-1靶点可以早日迎来重大突破。【智药研习社直播预告】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

抗体药物偶联物ASCO会议临床1期

2024-06-18

·BioSpace

Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging

Phio's Compound RXI-185 is designed to slow progression of UV induced collagen breakdown Marlborough, Massachusetts--(News - June 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, has been granted a skin care patent in South Korea. The patent, METHODS FOR TREATING AGING AND SKIN DISORDERS USING NUCLEIC ACIDS TARGETING MMP1, covers the INTASYL RXI-185 compound that treats aging and skin disorders, including photo-aging. RXI-185 is a potent silencer of MMP1 expression in the skin, interrupting ultraviolet radiation (UVR) induced collagen breakdown, thereby improving and/or slowing the progression for skin thickening, elasticity and wrinkles. This is an additional patent in a family of patents covering INTASYL compounds that target aging skin disorders. The Phio patent portfolio now consists of 81 issued patents, 77 of which cover the INTASYL siRNA gene silencing technology. The portfolio includes patents and applications broadly covering both the composition and methods of use of INTASYL compounds targeting immune checkpoint, cellular differentiation, and metabolism targets for ex vivo cell-based cancer immunotherapies. "Our patent portfolio for Phio's INTASYL siRNA technology is extensive and robust," said Robert Bitterman, CEO of Phio Pharmaceuticals. "The addition of this recent patent for treatment of photo-aging complements our current initiative in treating skin cancer." About Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL® RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. For additional information, visit the Company's website, . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Examples of forward-looking statements include statements regarding the use of RXI-185 to treat skin disorders and photo-aging. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law. Contact: Phio Pharmaceuticals Corp. ir@phiopharma.com PR Contact Michael Adams Bridge View Media adams@bridgeviewmedia.com To view the source version of this press release, please visit

免疫疗法